Mumbai — PharmEasy has released findings from a consumer study indicating increased adoption of branded substitute medicines, with users reporting savings of up to 60% on their medicine bills.
The study, based on user survey responses and platform data between January 1, 2023 and December 31, 2025, examined purchasing decisions between branded medicines and clinically equivalent lower-cost alternatives.
According to the findings, 86% of surveyed users reported visible savings after switching to branded substitutes. Many respondents indicated savings of up to 60%, particularly benefiting those managing chronic conditions requiring regular medication.
The study found sustained usage patterns, with 71% of respondents stating they had used branded substitutes for over a year. Additionally, 89% said they would recommend substitutes to others, and no respondents reported them to be less effective than branded medicines.
Platform data shows substitution rates rising from 22% in 2024 to 40% in 2025. Higher adoption was observed in categories such as diabetes, blood pressure and antibiotics. Repeat purchase trends suggest that substitution is becoming a routine choice rather than a one-time shift.
Gaurav Verma, Chief Business Officer at PharmEasy (API Holdings), said the findings reflect a shift toward value-based healthcare decisions, with cost savings often leading to long-term adoption based on user experience.
PharmEasy noted that the statistics are based on sales data from its platform and may not reflect broader market trends.
